POET Technologies Closes First Tranche of Convertible

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
40
POET Technologies Closes First Tranche of Convertible Debentures

NOT FOR DISSEMINATION TO U.S. NEWSWIRES OR DISCLOSURE IN THE UNITED STATES

TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“ POET ” or the “ Company ”) is pleased to announce that it has completed the first tranche closing of its previously announced private placement of 12.0% convertible unsecured debentures (the “ Convertible Debentures ”), brokered by the Company’s financial advisor IBK Capital. The Company raised approximately C$1.9 million through the first tranche closing. IBK Capital was paid a cash commission of 5.0% of the gross proceeds raised. Insiders of the Company and IBK Capital subscribed for over 47% of the first tranche of Convertible Debentures, including all of the Company’s board of directors and senior management team. Further indications of interest to date amounting to approximately C$1.6 million from investors who could not participate in the first tranche are expected to be included in subsequent tranches. The expected offering of subsequent tranches of Convertible Debentures over the next few months is intended to allow existing shareholders and new prospective investors to participate. Any subsequent tranches to be completed will be subject to the approval of the TSX Venture Exchange. For a complete description of the terms of the Convertible Debentures, refer to the Company’s press release of April 1, 2019.

The Convertible Debentures are subject to a hold period of four months expiring on August 4, 2019. The Convertible Debentures may be converted in accordance with their terms prior to the expiry of the hold period, but the common shares and warrants comprising the units issued on such conversion (as well as any common shares issued on exercise of such warrants) will be subject to the unexpired balance of the four month hold period.

Participation by the insiders in the first tranche closing of Convertible Debentures was considered a “related party transaction” pursuant to TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company was exempt from the requirements to obtain both formal valuation and minority shareholder approval in connection with such insider participation in reliance on sections 5.5(b) and 5.7(1)(a) of MI 61-101. A material change report was not filed in connection with the participation of the insiders in at least 21 days in advance of the first tranche closing of the Convertible Debentures, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the closing in an expeditious manner.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act "), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirements is available. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities within any jurisdiction, including the United States.

About POET Technologies Inc. POET Technologies is a developer and manufacturer of optical light source products for the sensing and data communications markets. Integration of optics and electronics is fundamental to increasing functional scaling and lowering the cost of current photonic solutions. POET believes that its approach to hybrid integration of devices, utilizing a novel dielectric platform and proven advanced wafer-level packaging techniques, enables substantial improvements in device cost, efficiency and performance. Optical engines based on this integrated approach have applications ranging from data centers to consumer products. POET is headquartered in Toronto, with operations in Ottawa, Silicon Valley, the United Kingdom, and Singapore. More information may be obtained at www.poet-technologies.com .

Shareholder Contact: Shelton Group Brett L. Perry sheltonir@sheltongroup.com Company Contact: Thomas R. Mika, EVP & CFO tm@poet-technologies.com

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding the success of the Company’s financing transactions and its ability to further financing steps described in this news release.  Such statements include the Company’s expectations with respect to use of proceeds from the financing, completion of additional tranches of Convertible Debentures, completion of the sale of its DenseLight subsidiary, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding financing activities, future growth, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the inability of the Company to cooperate effectively as described in this press release, operational risks in the completion of the Company’s anticipated projects, delays or changes in plans with respect to the development of the Company’s anticipated projects by the Company’s third-party relationships, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 - Fax: 416-322-5075

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 4

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
USFCR Wins 2026 Award for Federal Contracting Services

Updated Category News Views 7

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 3

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 2

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 7

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 28

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 5

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 5

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Crystal Risotti: Leading IT Compliance in Healthcare

Updated Category News Views 6

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSig Technologies Updates on Merger and Share Issuance Plans

Updated Category News Views 169

BioSig Technologies Provides Merger Update LOS ANGELES and VANCOUVER, British Columbia — BioSig Technologies, Inc. (NASDAQ: BSGM), recently provided a significant update regarding its merger with Streamex Exchange Corporation. The recent developments aim to clarify the status of the merger and ensure all shareholders are informed. Details of the Merger Finalization The...

Continue Reading
Al Hurra Cuts Jobs and Merges Iraq Channel Amid Budget Cuts

Updated Category News Views 136

Al Hurra Faces Major Workforce Reductions The parent organization of the Arabic language broadcaster Al Hurra has announced significant layoffs, resulting in the elimination of 160 positions. This decision comes in the wake of a 20% budget cut mandated by the U.S. Congress, as revealed by the company’s CEO in a message to staff. Understanding the Budget Cuts Dr. Jeffrey...

Continue Reading
Strategies for Success in Hinge Research Institute's 2025 Study

Updated Category News Views 627

Innovative Strategies Highlighted in Hinge Research's 2025 Study Hinge Research Institute stands at the forefront of research on professional services growth. With its recent 10th Annual High Growth Study, the institute has delivered crucial insights into how successful firms thrive in today’s rapidly evolving market. The study not only illustrates the growth potential...

Continue Reading
Psyence Biomed Celebrates Milestones in Psilocybin Development

Updated Category News Views 125

Recent Developments in Psyence Biomed's Journey In a significant update shared by Psyence Biomedical Ltd. (Nasdaq: PBM), the company has showcased its achievements, reflecting a positive trajectory in the realm of psychedelic-based therapeutics. Highlights from the update included the impressive valuation of their stake in PsyLabs, strong clinical trial progress, and a...

Continue Reading
Rugby Resources Limited Expands Private Placement Offerings

Updated Category News Views 146

Rugby Resources Limited Expands Private Placement Opportunities Rugby Resources Ltd. (TSX-V: RUG) has announced an important development regarding its private placement offering. Responding to high subscriber demand, the company's board has authorized an increase in the number of available units, raising the offering from 60 million units to an impressive 81.84 million...

Continue Reading